BackNeuroBo Pharmaceuticals Overview

NeuroBo Pharmaceuticals Total Liabilities

Track NeuroBo Pharmaceuticals's total liabilities ($6.4M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$6.45M
27.01% YoYΔ $-2.39M vs prior year quarter

Peer trimmed avg / median

Loading

NeuroBo Pharmaceuticals Total Liabilities History

Loading

NeuroBo Pharmaceuticals vs. peers: Total Liabilities Comparison

Loading

NeuroBo Pharmaceuticals Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

NeuroBo Pharmaceuticals (NRBO) FAQ

As of the most recent data (June 2026), NRBO shows a total liabilities of $6.4M. That compares with $8.8M in the prior-year period — down 27.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NRBO's total liabilities is now $6.4M (was $8.8M) — a 27.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether NeuroBo Pharmaceuticals is outperforming or lagging.

Tracking NRBO's total liabilities over time shows whether NeuroBo Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $6.4M That compares with $8.8M in the prior-year period — down 27.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has NeuroBo Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $6.4M) with ownership activity and broader fundamentals.

NeuroBo Pharmaceuticals's total liabilities is $6.4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.